NasdaqGS:ERASBiotechs
Erasca (ERAS) Could Be 40% Below Fair Value On Lawsuit And Trial Risk
Erasca (ERAS) is under pressure after a series of securities class action filings tied to its lead oncology candidate ERAS-0015, patent and trade secret allegations, and preliminary trial data that included a reported patient death.
See our latest analysis for Erasca.
Erasca’s recent legal headlines came after a period of very strong momentum, with a year to date share price return of 319.22% and a very large 1 year total shareholder return. However, the 90 day share price return of 0.53%...